At a glance
The respiratory vaccine codes and crosswalk tables for RSV, COVID-19, and Influenza are provided in the following summary tables.
Respiratory Syncytial Virus (RSV) Codes and Crosswalks
The following table includes the RSV codes and crosswalks included in the CDC IIS Vaccine Code Sets. Note that the CPT codes shown are not mapped to the NDC codes, but are mapped to the CVX codes shown. CPT codes provided in the vaccine code sets are to assist with code categorizations and are not intended to represent billable codes.
Get email updates
Sign up for our email newsletter below.
Download the RSV Crosswalk table
Respiratory Syncytial Virus (RSV) Vaccine Codes Fall Season
| CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 303 | Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free | Arexvy | GlaxoSmithKline Biologicals SA | SKB | 58160-0848-11 | 58160-0723-03 | VIAL, 0.5 mL, reconstituted | 90679 | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use |
| 305 | Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free | Abrysvo | Pfizer Laboratories Div Pfizer Inc | PFR | 00069-0344-01 00069-0344-05 00069-0344-10 |
00069-0207-01 | VIAL, 0.5 mL, reconstituted | 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use |
| 305 | Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free | Abrysvo | Pfizer Laboratories Div Pfizer Inc | PFR | 00069-2465-01 00069-2465-10 |
00069-2465-19 | VIAL, 0.5 mL, SINGLE-DOSE | 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use |
| 326 | Respiratory syncytial virus (RSV), mRNA, injectable, preservative free | mRESVIA | Moderna US, INC. | MOD | 80777-0345-90 80777-0345-96 80777-0345-61 80777-0345-62 80777-0345-63 |
80777-0345-01 | SYRINGE, 0.5 mL | 90683 | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use |
Respiratory Syncytial Virus (RSV) Monoclonal Antibody Codes Fall Season (*)
| CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 306 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-0575-15 | 49281-0575-00 | SYRINGE, 0.5 mL | 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use |
| 307 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-0574-15 | 49281-0574-88 | SYRINGE, 1 mL | 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use |
| 332 | Respiratory syncytial virus (RSV), monoclonal antibody, IgG1κ, (clesrovimab-cfor), 0.7 mL, neonate and infant, preservative free | ENFLONSIA | Merck Sharp & Dohme LLC | MSD | 00006-5073-01 00006-5073-02 |
00006-5073-99 | SYRINGE, 0.7 mL | 90382 | Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use |
(*) The BEYFORTUS nirsevimab and ENFLONSIA clesrovimab monoclonal antibody codes are included in the vaccine code set in a manner similar to regular vaccines to enable reporting or other program data exchange in accordance with ACIP and CDC guidelines.
Respiratory Syncytial Virus (RSV) Unspecified Codes
| CVX Code | CVX Description | CVX Note |
|---|---|---|
| 314 | Respiratory syncytial virus (RSV) vaccine, unspecified | Unspecified, for historic records where the specific vaccine administered is not known |
| 315 | Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified | Unspecified, for historic records where the specific RSV MAB administered is not known |
| 304 | Respiratory syncytial virus (RSV), unspecified | Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administered |
Fall 2024 COVID-19 Vaccine Codes and Crosswalks
The following table provides a preview and summary of the vaccine codes and crosswalks for Fall 2024 COVID-19 vaccines.
Note: Codes in the following table are effective and published in the full vaccine code sets only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). Additional code details and fields values are included in the vaccine code sets published.
Download the Fall 2024 COVID-19 Vaccine Code Crosswalk table
| Manufacturer (MVX) | Product Label Tradename (**) | CVX Code | CVX Term Description | CVX Short Description | NDC Virus Strain | UoS NDC10 UoS NDC11 |
Packaging | UoU NDC10 UoU NDC11 |
Age Cohort; Presentation |
CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer (PFR) |
COMIRNATY (COVID-19 Vaccine, mRNA, 2024-2025 Formula), no freeze formulation | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron KP.2 | 0069-2432-10 00069-2432-10 |
CARTON, 10 PRE-FILLED GLASS SYRINGES | 0069-2432-01 00069-2432-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, GLASS, 30 mcg/0.3 mL - DO NOT FREEZE |
91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) | 310 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron KP.2 | 59267-4438-2 59267-4438-02 |
CARTON, 10 SINGLE-DOSE VIALS | 59267-4438-1 59267-4438-01 |
Ages 5 through 11 years; VIAL, SINGLE-DOSE, 10 mcg/0.3 mL DO NOT DILUTE |
91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) | 308 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron KP.2 | 59267-4426-2 59267-4426-02 |
CARTON, 10 MULTI-DOSE VIALS | 59267-4426-1 59267-4426-01 |
Ages 6 months through 4 years; VIAL, MULTI-DOSE, 3 DOSES, 3 mcg/0.3 mL AFTER DILUTION |
91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Moderna (MOD) |
SPIKEVAX (COVID-19 Vaccine, mRNA, 2024-2025 Formula) | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron KP.2 | 80777-110-96 80777-0110-96 |
CARTON, 10 PRE-FILLED SYRINGES | 80777-110-01 80777-0110-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
SPIKEVAX (COVID-19 Vaccine, mRNA, 2024-2025 Formula) | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron KP.2 | 80777-110-93 80777-0110-93 |
CARTON, 10 PRE-FILLED SYRINGES | 80777-110-01 80777-0110-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Moderna COVID-19 Vaccine (2024-2025 Formula) | 311 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | SARS-CoV-2 virus strain Omicron KP.2 | 80777-291-80 80777-0291-80 |
CARTON, 10 PRE-FILLED SYRINGES | 80777-291-09 80777-0291-09 |
Ages 6 months through 11 years; SYRINGE, PRE-FILLED, 25 mcg/0.25 mL |
91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use |
| Moderna (MOD) |
Moderna COVID-19 Vaccine (2024-2025 Formula) | 311 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | SARS-CoV-2 virus strain Omicron KP.2 | 80777-291-81 80777-0291-81 |
CARTON, 10 BLISTER-SEALED PRE-FILLED SYRINGES | 80777-291-09 80777-0291-09 |
Ages 6 months through 11 years; SYRINGE, PRE-FILLED, 25 mcg/0.25 mL |
91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use |
| Novavax (NVX) |
Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) | 313 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron JN.1 | 80631-107-10 80631-0107-10 |
CARTON, 10 PRE-FILLED GLASS SYRINGES | 80631-107-01 80631-0107-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 Ml DO NOT FREEZE |
91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use |
(*) Vaccines products and codes added to this table have FDA BLA licensure approval or Emergency Use Authorization (EUA).
(**) Product Label Tradename: If the manufacturer name is included in the tradename, the vaccine product is provided under EUA. Other tradenames are for vaccine products provided under BLA licensure.
Other COVID-19 Vaccine Related Codes and Links
Information regarding currently active EUA Recipient and Caregiver Fact Sheet URLs and Codes can be found here.
Registered users can access COVID-19 vaccine lot numbers and expiration dates provided to CDC by the vaccine manufacturer.
Information regarding Previous COVID-19 pandemic Emergency Use Authorization (EUA) and BLA codes and crosswalks can be found here.
2025/2026 Seasonal Influenza Codes and Crosswalk
This format includes all seasonal influenza vaccines for the season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine.
(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown. These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.
Download the Seasonal Influenza Crosswalk table
Influenza Vaccines for Season 2025/2026 (Northern Hemisphere)
| CVX Code | CVX Short Description | CVX Long Name | Sale Proprietary Name | Sale Labeler | MVX Code | Sale NDC11 | Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|---|
| 141 | Influenza, split virus, trivalent, preservative | Influenza, split virus, trivalent, injectable, contains preservative | Afluria | Seqirus PTY LTD. | SEQ | 33332-125-10 33332-0125-10 |
33332-125-11 33332-0125-11 |
VIAL, 5 mL, MULTI-DOSE | 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use |
| 140 | Influenza, split virus, trivalent, PF | Influenza, split virus, trivalent, injectable, preservative free | Afluria | Seqirus PTY LTD. | SEQ | 33332-025-03 33332-0025-03 |
33332-025-04 33332-0025-04 |
SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 168 | Influenza, adjuvanted, trivalent, PF | Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free | FLUAD | Seqirus, Inc. | SEQ | 70461-025-03 70461-0025-03 |
70461-025-04 70461-0025-04 |
SYRINGE, 0.5mL | 90653 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use |
| 140 | Influenza, split virus, trivalent, PF | Influenza, split virus, trivalent, injectable, preservative free | FLUARIX | GlaxoSmithKline Biologicals SA | SKB | (*) NA |
(*) NA |
SYRINGE, 0.5mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 155 | Influenza, recombinant, trivalent, PF | Influenza, recombinant, trivalent, injectable, preservative free | FLUBLOK TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | (*) 49281-725-10 49281-0725-10 |
(*) 49281-725-88 49281-0725-88 |
SYRINGE, 0.5 mL | 90673 | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use |
| 153 | Influenza, MDCK, trivalent, PF | Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free | Flucelvax | Seqirus Inc. | SEQ | 70461-655-03 70461-0655-03 |
70461-655-04 70461-0655-04 |
SYRINGE, 0.5 mL | 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
| 320 | Influenza, MDCK, trivalent, preservative | Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservative | Flucelvax | Seqirus Inc. | SEQ | 70461-555-10 70461-0555-10 |
70461-555-11 70461-0555-11 |
VIAL, 5 mL, MULTI-DOSE | 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
| 140 | Influenza, split virus, trivalent, PF | Influenza, split virus, trivalent, injectable, preservative free | FLULAVAL | ID Biomedical Corporation of Quebec | IDB | 19515-904-52 19515-0904-52 |
19515-904-41 19515-0904-41 |
SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 135 | Influenza, high-dose, trivalent, PF | Influenza, high-dose, split virus, trivalent, injectable, preservative free | FLUZONE HIGH DOSE NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-125-65 49281-0125-65 |
49281-125-88 49281-0125-88 |
SYRINGE, 0.5 mL | 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use |
| 141 | Influenza, split virus, trivalent, preservative | Influenza, split virus, trivalent, injectable, contains preservative | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-643-15 49281-0643-15 |
49281-643-78 49281-0643-78 |
VIAL, 5 mL, MULTI-DOSE | 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use |
| 140 | Influenza, split virus, trivalent, PF | Influenza, split virus, trivalent, injectable, preservative free | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-425-50 49281-0425-50 |
49281-425-88 49281-0425-88 |
SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 111 | Influenza, live, trivalent, intranasal, PF | Influenza, live, trivalent, intranasal, preservative free | FluMist trivalent | MedImmune, Inc. (AstraZeneca) |
MED | (*) 66019-112-10 66019-0112-10 |
(*) 66019-112-00 66019-0112-00 |
CARTON OF 10 APPLICATOR, 0.2 mL | 90660 | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use |
| 333 | Influenza, live, trivalent, intranasal, self/caregiver admin, PF | Influenza, live, trivalent, intranasal, self or caregiver administered, preservative free | FluMist trivalent, (self/caregiver administered) | MedImmune, Inc. (AstraZeneca) |
MED | (*) 66019-112-51 66019-0112-51 |
(*)(**) 66019-112-51 66019-0112-51 |
CARTON OF 1 APPLICATOR, 0.2 mL | NA | NA |
(*) NDCs are not yet available in the vaccine code set files. Vaccine NDCs are added to the code sets once the NDCs have been approved by the FDA and arelisted in both the FDA drug files and in DailyMed.
(**) The Unit of Use (UoU) for the FluMist self or caregiver administered vaccine has been listed with the same NDC code as the Unit of Sale (UoS) NDC rather than the actual NDC UoU which is the same as for the FluMist HCP administered product. This allows mapping to a different, new CVX code for the self or caregiver administered FluMist vaccine.
Southern Hemisphere 2025 Influenza Season
| CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 331 | influenza, Southern Hemisphere, preservative free | FLUZONE TRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0325-50 | 49281-0325-88 | SYRINGE, 0.5 mL | NA | NA |